Ferrokin Biosciences, a San Carlos Calif. company that makes compounds to treat iron overload in patients with anemia, received $8.4 million of what it hopes will be a $15 million first-round of funding from Clarus Ventures, Burrill & Co. and Celegene Inc.
Iron overload is a common side effect of repeated transfusions used to treat certain types of anemia. The company doesn't have a website, and very little information on it is available.